4D Molecular Therapeutics (FDMT) Cash from Operations (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Cash from Operations data on file, last reported at 68125000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 42.65% year-over-year to 68125000.0 in Q1 2026; TTM through Mar 2026 was 129449000.0, a 15.53% increase from a year earlier, with the FY2025 full-year figure at 109082000.0, up 18.95% from the prior year.
• Cash from Operations for Q1 2026 stood at 68125000.0, down from 28551000.0 in the prior quarter.
• Over the last five years, Cash from Operations for FDMT reached as high as 28551000.0 in Q4 2025 and fell as low as 68125000.0 in Q1 2026.
• Historically, Cash from Operations has averaged 27898176.47 across 5 years, with a median of 27906000.0 in 2023.
• Across the five-year window, Cash from Operations plunged 2409.91% in 2024 and soared 162.25% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 22214000.0 in 2022, then retreated by 10.97% to 24650000.0 in 2023, then plunged by 86.06% to 45863000.0 in 2024, then surged by 162.25% to 28551000.0 in 2025, then tumbled by 338.61% to 68125000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 68125000.0 in Q1 2026, 28551000.0 in Q4 2025, and 46498000.0 in Q3 2025.